Colorectal CancerMIRACLeNCT05164887
Microbiota Implementation to Reduce Anastomotic Colorectal Leaks (MIRACLe)
An observational study of Colorectal Cancer and Surgery, run by S.Eugenio Hospital at 1 site in Italy.
Trial summary
Aim of this study is to implement the intestinal microbiota by perioperative administration of probiotics, oral antibiotics and low volume mechanical preparation in order to reduce the incidence of colorectal anastomotic leaks and dehiscences. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Colorectal Cancer, Surgery, LAP
- What is being tested?
- Laparoscopic colorectal resection
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- How many people
- 131 participants
- Where
- 1 siteItaly
- Study dates
- 1 Dec 2020to 30 Nov 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients affected by colorectal cancer submitted to laparoscopic resections with ileo- colo- rectal anastomoses
Who may be able to join
- Age > 18 years
- ASA I - II - III
- Colorectal cancer
- Elective surgery
- Laparoscopic resections
Who cannot join
- Age < 18 years
- ASA IV
- Emergency surgery
- Laparotomic resections
- Diverticular disease or IBD
- Hartmann or Miles procedures
- Stomies
- Major intraoperative complications
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Can we Manipulate the Bowel Microbiota and Prevent Anastomotic Leakage in Colorectal Laparoscopic Surgery? Preliminary Results of the MIRACLe Study.
Aim of this study is to implement the intestinal microbiota by perioperative administration of probiotics, oral antibiotics and low volume mechanical preparation in order to reduce the incidence of colorectal anastomotic leaks and dehiscences.
Read the detailed description
Anastomotic leaks and dehiscences are still the most frequent complication of colorectal surgery and have a multifactorial etiology.
Microbiota refers to the totality of microorganisms in a defined environment. The Microbiome represents the set of genomes of all microorganisms and its environmental relationships. The microbiome performs various and important functions, but above all it contributes to maintaining the integrity of the mucous barrier of the intestinal epithelium.
The composition, biodiversity and functions of the intestinal microbiota vary both longitudinally along the entire intestinal tract from the mouth to the anus, and radially from the muco-epithelial layer to the intestinal lumen. This biodiversity fluctuates with daily variations following various conditions such as diet, physical activity, interactions with people and animals, etc., but remains stable in healthy subjects.
Particular conditions can determine a phenotypic shift of some bacterial families with the development of species with different characteristics, potentially pathogenic which can favor the onset of fistulas and anastomotic dehiscences in experimental setting.
It is known experimentally that the surgical act alone causes a greater change in the composition of the intestinal microbiota. The way in which surgical stress alters the microbiome lies in the mechanisms which the host and the microorganisms communicate. It has recently been shown that mechanical bowel preparation and the administration of antibiotics have an influence on the microbiome. In particular, the mechanical preparation with polyethylene glycol (PEG) and oral antibiotics (OA) can constitute a positive element for surgical outcomes, while intravenous antibiotics very often affect microbiota negatively.
The intestinal flora influence the healing of intestinal anastomoses and non-pathogenic saprophytes allow anastomoses to withstand increased endoluminal pressures. Based on this, it has been shown that the postoperative implementation of bifidobacteria improves functional recovery, reduces the inflammatory response and improves the composition of the fecal microbiota in patients undergoing colorectal surgery.
Based on these considerations, this study aims to modify the preoperative preparation by implementing the intestinal microbiota in order to evaluate the incidence of anastomotic leaks.
The patient's treatment will be divided into 3 phases: preoperative, intraoperative and postoperative.
Preoperative treatment The preoperative phase runs from the fifth preoperative day (-5) to day -1.
In this phase, patients will undergo microbiota implementation through preoperative preparation consisting of:
- Oral probiotics: Streptococcus thermophilus; Bifidobacterium brevis; Bifidobacterium longum; Bifidobacterium infantis; Lactobacillus acidophilus; Lactobacillus plantarum; Lactobacillus paracasei; Lactobacillus delbrueckii subsp. Bulgaricus (VSL # 3) 4,4gr, equal to 450 billion live bacterial cells, every 12 hours from the day -5.
- Oral antibiotic prophylaxis with Amoxicillin / Ac. Clavulanic (Augmentin), 1g every 12 hours + Metronidazole (Flagyl), 250 mg every 8 hours in the day -1.
- Mechanical preparation with Polyethylene Glycol - low volume.
Intraoperative treatment - Surgical technique Under general anesthesia and hemodynamic monitoring, pneumoperitoneum induction and positioning of the trocars necessary for the execution of the surgery will be carried out. The number and location of the trocars will be determined by the type of intervention to be performed and the operator's preferences. After an abdominal exploration, we will continue with the resective phase of the intervention depending on the location of the disease and in compliance with the oncological radicality criteria. The anastomosis will be performed according to the principles of good vascularization and reconstruction without tension or torsion.
The anastomosis will be:
- Intracorporeal (mechanical / manual) if ileo-colic.
- Intra- or extra-corporeal (mechanical or manual respectively) if colocolic, after resection of the transverse, splenic or segmental flexure of the left colon.
- Transanal (mechanical) if colorectal, after left hemicolectomy, sigmoidectomy or resection of the rectum (both intra- and subperitoneal).
The positioning of nasogastric tube, drains, bladder catheter, central vascular accesses, whose management will be at the discretion of the operators, is subject to the Enhanced Recovery After Surgery (ERAS®) principles in use in the centers participating in the study.
- Intraoperative phase On the morning of the surgery, antibiotics will be administered: Amoxicillin / Ac. Clavulanic 1g + Metronidazole 250 mg orally, about 2 hours before the induction of anesthesia.
Anastomotic endoluminal instillation of a dose (4.4 g) of the probiotic used in the preoperative phase, diluted in 20cc of sterile physiological solution, will also be performed. This dose will be equally distributed in the 2 intestinal stumps. The instillation will take place using a special laparoscopic cannula.
Postoperative treatment The postoperative management of patients will be based on compliance with Enhanced Recovery After Surgery (ERAS®) principles, where applicable (nasogastric tube removal on first postoperative day, bladder catheter removal on first postoperative day, early feeding, mobilization, etc.).
The oral antibiotic prophylaxis will be continued until day +1, while the administration of probiotics will take place until day +4.
- Conditions
- Colorectal Cancer, Surgery, LAP, Anastomotic Leak, Microbial Substitution
- Being tested
- Laparoscopic colorectal resection
- Medical subject headings
- Colorectal Neoplasms, Anastomotic Leak
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Laparoscopic colorectal resectionProcedure or surgery
Also called Perioperative bowel preparation
the patients candidate to laparoscopic colorectal resection for cancer are perioperatively treated with mechanical bowel preparation, oral antibiotics and administration of probiotics
| Study group | Role | What they receive |
|---|---|---|
| MIRACLe patients | Patient affected by colorectal cancer submitted to laparoscopic resection with MBP + OA + perioperative Probiotics administration.
MBP = oral polyphosphate 500ml preoperative OA = Amoxicillin/Clavulanic acid 1g x 2 + metronidazole 250mg x 3 Probiotics = Streptococcus thermophilus; Bifidobacterium breve; Bifidobacterium longum; Bifidobacterium infantis; Lactobacillus acidophilus; Lactobacillus plantarum; Lactobacillus paracasei; Lactobacillus delbrueckii subsp. Bulgaricus 4,4g x 2 Receives: Procedure: Laparoscopic colorectal resection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Fistulas and Anastomotic Leaks
Evaluation of incidence of AL compared to a group of 500 colorectal resection in patient prepared with ev antibiotics, no MBP and without probiotics administration
Measured: 4 weeks
Secondary outcomes (1)
Incidence of SSI
Measuring incidence of surgical site infections compared to the control group
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Dec 2021
- Study start1 Dec 2020
- Primary completion30 Nov 2021
- Study completion30 Nov 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 131 participants (actual)
Sponsor and investigators
- Lead sponsor
- S.Eugenio Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Domenico Spoletini, M.D. PhD, Michele Grieco, M.D., Rosa Marcellinaro, M.D PhD, Andrea Mingoli, M.D. PhD, Rosa Menditto, M.D., Vincenzo Napoleone, PhD, Gioia Brachini, M.D. PhD
- Responsible party
- Principal investigator, Massimo Carlini, S.Eugenio Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05164887
- Sponsor's protocol ID
- 1.0
- Acronym
- MIRACLe
- Status last verified
- Apr 2023
- First submitted
- 3 Dec 2021
- Last updated
- 18 Apr 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Can we Manipulate the Bowel Microbiota and Prevent Anastomotic Leakage in Colorectal Laparoscopic Surgery? Preliminary Results of the MIRACLe Study.
- ClinicalTrials.gov ID
- NCT05164887
- Acronym / sponsor ID
- MIRACLe / 1.0
- Conditions
- Colorectal Cancer, Surgery, LAP, Anastomotic Leak, Microbial Substitution
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 131 participants (actual)
- Lead sponsor
- S.Eugenio HospitalUniversity, hospital or other
- Collaborators
- Domenico Spoletini, M.D. PhD, Michele Grieco, M.D., Rosa Marcellinaro, M.D PhD, Andrea Mingoli, M.D. PhD, Rosa Menditto, M.D., Vincenzo Napoleone, PhD, Gioia Brachini, M.D. PhD
- Study start
- 1 Dec 2020 (actual)
- Primary completion
- 30 Nov 2021 (actual)
- Study completion
- 30 Nov 2022 (actual)
- First posted
- 21 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aim of this study is to implement the intestinal microbiota by perioperative administration of probiotics, oral antibiotics and low volume mechanical preparation in order to reduce the incidence of colorectal anastomotic leaks and dehiscences.
Detailed description
Anastomotic leaks and dehiscences are still the most frequent complication of colorectal surgery and have a multifactorial etiology.
Microbiota refers to the totality of microorganisms in a defined environment. The Microbiome represents the set of genomes of all microorganisms and its environmental relationships. The microbiome performs various and important functions, but above all it contributes to maintaining the integrity of the mucous barrier of the intestinal epithelium.
The composition, biodiversity and functions of the intestinal microbiota vary both longitudinally along the entire intestinal tract from the mouth to the anus, and radially from the muco-epithelial layer to the intestinal lumen. This biodiversity fluctuates with daily variations following various conditions such as diet, physical activity, interactions with people and animals, etc., but remains stable in healthy subjects.
Particular conditions can determine a phenotypic shift of some bacterial families with the development of species with different characteristics, potentially pathogenic which can favor the onset of fistulas and anastomotic dehiscences in experimental setting.
It is known experimentally that the surgical act alone causes a greater change in the composition of the intestinal microbiota. The way in which surgical stress alters the microbiome lies in the mechanisms which the host and the microorganisms communicate. It has recently been shown that mechanical bowel preparation and the administration of antibiotics have an influence on the microbiome. In particular, the mechanical preparation with polyethylene glycol (PEG) and oral antibiotics (OA) can constitute a positive element for surgical outcomes, while intravenous antibiotics very often affect microbiota negatively.
The intestinal flora influence the healing of intestinal anastomoses and non-pathogenic saprophytes allow anastomoses to withstand increased endoluminal pressures. Based on this, it has been shown that the postoperative implementation of bifidobacteria improves functional recovery, reduces the inflammatory response and improves the composition of the fecal microbiota in patients undergoing colorectal surgery.
Based on these considerations, this study aims to modify the preoperative preparation by implementing the intestinal microbiota in order to evaluate the incidence of anastomotic leaks.
The patient's treatment will be divided into 3 phases: preoperative, intraoperative and postoperative.
Preoperative treatment The preoperative phase runs from the fifth preoperative day (-5) to day -1.
In this phase, patients will undergo microbiota implementation through preoperative preparation consisting of:
- Oral probiotics: Streptococcus thermophilus; Bifidobacterium brevis; Bifidobacterium longum; Bifidobacterium infantis; Lactobacillus acidophilus; Lactobacillus plantarum; Lactobacillus paracasei; Lactobacillus delbrueckii subsp. Bulgaricus (VSL # 3) 4,4gr, equal to 450 billion live bacterial cells, every 12 hours from the day -5.
- Oral antibiotic prophylaxis with Amoxicillin / Ac. Clavulanic (Augmentin), 1g every 12 hours + Metronidazole (Flagyl), 250 mg every 8 hours in the day -1.
- Mechanical preparation with Polyethylene Glycol - low volume.
Intraoperative treatment - Surgical technique Under general anesthesia and hemodynamic monitoring, pneumoperitoneum induction and positioning of the trocars necessary for the execution of the surgery will be carried out. The number and location of the trocars will be determined by the type of intervention to be performed and the operator's preferences. After an abdominal exploration, we will continue with the resective phase of the intervention depending on the location of the disease and in compliance with the oncological radicality criteria. The anastomosis will be performed according to the principles of good vascularization and reconstruction without tension or torsion.
The anastomosis will be:
- Intracorporeal (mechanical / manual) if ileo-colic.
- Intra- or extra-corporeal (mechanical or manual respectively) if colocolic, after resection of the transverse, splenic or segmental flexure of the left colon.
- Transanal (mechanical) if colorectal, after left hemicolectomy, sigmoidectomy or resection of the rectum (both intra- and subperitoneal).
The positioning of nasogastric tube, drains, bladder catheter, central vascular accesses, whose management will be at the discretion of the operators, is subject to the Enhanced Recovery After Surgery (ERAS®) principles in use in the centers participating in the study.
- Intraoperative phase On the morning of the surgery, antibiotics will be administered: Amoxicillin / Ac. Clavulanic 1g + Metronidazole 250 mg orally, about 2 hours before the induction of anesthesia.
Anastomotic endoluminal instillation of a dose (4.4 g) of the probiotic used in the preoperative phase, diluted in 20cc of sterile physiological solution, will also be performed. This dose will be equally distributed in the 2 intestinal stumps. The instillation will take place using a special laparoscopic cannula.
Postoperative treatment The postoperative management of patients will be based on compliance with Enhanced Recovery After Surgery (ERAS®) principles, where applicable (nasogastric tube removal on first postoperative day, bladder catheter removal on first postoperative day, early feeding, mobilization, etc.).
The oral antibiotic prophylaxis will be continued until day +1, while the administration of probiotics will take place until day +4.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| MIRACLe patients | – | Procedure: Laparoscopic colorectal resectionPatient affected by colorectal cancer submitted to laparoscopic resection with MBP + OA + perioperative Probiotics administration. MBP = oral polyphosphate 500ml preoperative OA = Amoxicillin/Clavulanic acid 1g x 2 + metronidazole 250mg x 3 Probiotics = Streptococcus thermophilus; Bifidobacterium breve; Bifidobacterium longum; Bifidobacterium infantis; Lactobacillus acidophilus; Lactobacillus plantarum; Lactobacillus paracasei; Lactobacillus delbrueckii subsp. Bulgaricus 4,4g x 2 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients affected by colorectal cancer submitted to laparoscopic resections with ileo- colo- rectal anastomoses
Key inclusion criteria (5 listed)
- Age > 18 years
- ASA I - II - III
- Colorectal cancer
- Elective surgery
- Laparoscopic resections
Key exclusion criteria (8 listed)
- Age < 18 years
- ASA IV
- Emergency surgery
- Laparotomic resections
- Diverticular disease or IBD
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Laparoscopic colorectal resectionAlso: Perioperative bowel preparationthe patients candidate to laparoscopic colorectal resection for cancer are perioperatively treated with mechanical bowel preparation, oral antibiotics and administration of probiotics | Procedure or surgery | MIRACLe patients |
Primary outcome
Incidence of Fistulas and Anastomotic Leaks
Time frame: 4 weeks
Evaluation of incidence of AL compared to a group of 500 colorectal resection in patient prepared with ev antibiotics, no MBP and without probiotics administration
1 secondary outcome
Incidence of SSI
Time frame: 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Apr 2023.
- Individual participant dataSharing planned: No
Related trials for Colorectal Cancer
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 1
A Study of MGC030 in Participants With Advanced Solid Tumors
Urothelial Cancer, GastroEsophageal Cancer
Active, not recruitingObservational study
The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer
Prostate Cancer, BRCA Mutation
RecruitingObservational study
ABCSG R07 Rectal Cancer Registry
Rectal Cancer, Adenocarcinoma of Rectum
Recruiting
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Cancer, Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer and Surgery, run by S.Eugenio Hospital at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Fistulas and Anastomotic Leaks (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2023.